Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

A majority of Americans have experienced the frustration of getting a healthcare insurance denial, often times finding no ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer recently recalibrated its evaluation score, a nod to shifting trends in the market and its own financial pulse. The ...